Color Health, Inc. (founded as Color Genomics) is an American healthcare company focused on cancer care delivery. The company operates a Virtual Cancer Clinic that provides services in cancer prevention, detection, screening, diagnosis, and survivorship care.
Color was co-founded in 2015 by Elad Gil, Nish Bhat, Taylor Sittler, and Othman Laraki, who serves as the company's CEO, in Burlingame, California.
In November 2021, the company raised $100 million in a Series E financing round led by General Catalyst.
In 2023, Color refocused its efforts from population genomics and COVID-19 testing to cancer care delivery, introducing its Virtual Cancer Clinic, a wholly-owned, vertically integrated cancer care platform that offers early detection, oncology based care, and survivorship support as an employer-offered health care benefit.
In 2023, Color Health launched its Virtual Cancer Clinic to provide cancer risk assessment, early detection, treatment coordination, and survivorship support. Care is delivered in accordance with established clinical guidelines by oncology-trained clinicians, primary care physicians, and genetic counselors licensed in all 50 U.S. states.
According to the company, first-year participation typically ranges from 20 to 30 percent of eligible individuals, with reported increases in screening adherence of up to 77 percent and shorter timelines from screening to diagnosis by up to 55 percent.
External reporting has noted that Color piloted the use of artificial intelligence tools to generate cancer screening and diagnostic plans, with the goal of reducing missed workups and creating standardized recommendations.
The Virtual Cancer Clinic also includes behavioral health support programs, a national imaging network, and care advocacy services.
In 2025, Color presented findings at the American Society of Clinical Oncology (ASCO) annual meeting from telehealth-based cancer screening programs for colorectal and lung cancers. These initiatives used at-home testing and virtual assessments to increase access to early detection services.
In 2020, Color redirected its existing laboratory and logistics operations to focus on COVID-19 testing. The company operated a CLIA-certified laboratory and some of the highest-capacity testing sites in the United States at the time.
Color provided testing for the City of San Francisco's CityTestSF program, Alameda County Health Services, and several universities and employers, including the University of Southern California and United Airlines.
By 2022, the company had processed millions of tests nationwide, though demand for testing declined and operations were scaled back.
Color's initial products focused on affordable genetic testing for hereditary cancer. Its CLIA-certified and CAP-accredited laboratory continues to provide genomic testing and genetic counseling.
The company's tests analyze genes associated with hereditary cancer syndromes, including BRCA1 and BRCA2, as well as 27 other genes associated with breast, prostate, colon, uterine, stomach, melanoma, pancreatic, and ovarian cancers.
Since 2018, Color has been a genome center for the National Institutes of Health's All of Us Research Program, which aims to sequence one million or more individuals in the United States to advance precision medicine research.
In 2019, Color was awarded responsibility for delivering genetic counseling across the All of Us program.
The company has participated in research initiatives, including:
Color also contributes anonymized variants to ClinVar, a database managed by the National Center for Biotechnology Information (NCBI) at the National Institutes of Health (NIH).